Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids
Public ClinicalTrials.gov record NCT05348200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids
Study identification
- NCT ID
- NCT05348200
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Citius Pharmaceuticals, Inc.
- Industry
- Enrollment
- 304 participants
Conditions and interventions
Conditions
Interventions
- Monad 1 Drug
- Monad 2 Drug
- Monad 3 Drug
- Combination - CITI-002 (low dose) Drug
- Combination - CITI-002 (high dose) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2022
- Primary completion
- Apr 19, 2023
- Completion
- May 16, 2023
- Last update posted
- Aug 30, 2023
2022 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site #01 | Huntsville | Alabama | 35801 | — |
| Site #07 | Tucson | Arizona | 85715 | — |
| Site #06 | Chula Vista | California | 91910 | — |
| Site #09 | Pomona | California | 91767 | — |
| Site #16 | San Diego | California | 92103 | — |
| Site #03 | San Diego | California | 92123 | — |
| Site #05 | West Palm Beach | Florida | 33409 | — |
| Site #10 | Covington | Louisiana | 70433 | — |
| Site #12 | Prairieville | Louisiana | 70769 | — |
| Site #02 | Wyoming | Michigan | 49519 | — |
| Site #14 | Gulfport | Mississippi | 39503 | — |
| Site #08 | Omaha | Nebraska | 68114 | — |
| Site #11 | Mentor | Ohio | 44060 | — |
| Site #13 | Tulsa | Oklahoma | 74133 | — |
| Site #04 | Harrisburg | Pennsylvania | 17110 | — |
| Site #15 | McKinney | Texas | 75070 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05348200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05348200 live on ClinicalTrials.gov.